China's sweeping clampdown of its tech sector at a time when its economy is slowing has helped push a global gauge of emerging-market shares to a 17-year relative low against developed-market peers
Increased investor concerns about China and a widening vaccination gap will keep pressure on emerging-market assets relative to their developed peers, according to some market participants.
China’s sweeping clampdown of its technology sector at a time when its economy is slowing has helped push a global gauge of emerging-market shares to a 17-year relative low against their developed-market peers. The spread of coronavirus variants has also weighed, with vaccine rollouts in developing nations lagging those in the likes of North America and Europe.
US and European stock markets are expected to continue to outperform, as advanced economies rebound, travel resumes and vaccinations creep closer to herd immunity.
“We forecast developed market outperformance over the remainder of the year,” said Andrew Sheets, chief cross-asset strategist with Morgan Stanley. “Emerging markets face more pressure from Covid, and more uncertainty around new variants, given lower vaccination rates.”
The MSCI Emerging Markets Index -- with about a third of its weight in Chinese names -- briefly fell into negative territory for the year last week, while the MSCI World Index of developed-market stocks is up about 15%.
The MSCI Emerging Markets Currency Index has fallen more than 1% from a record in June while the U.S. dollar has advanced -- a traditional headwind for developing nations.
No comments:
Post a Comment